Exosomm develops bioactive nutritional ingredients based on natural milk exosomes for the medical food and nutraceutical sectors. The company utilizes a patented, chemical-free technology to isolate these natural nanoparticles from whey, a byproduct of the cheese-making industry, ensuring the preservation of their active cargo. These milk-derived exosomes function as durable biological carriers for microRNAs, which naturally regulate immune responses and facilitate targeted intercellular communication.
The company’s flagship solution targets Inflammatory Bowel Diseases (IBD), such as Crohn's and Colitis, providing a non-synthetic method to reduce inflammation scores and extend remission periods. By upcycling dairy industry byproducts, the platform delivers a sustainable and scalable source of functional ingredients with high bioavailability and stability. This approach offers a clinically validated, food-based alternative for managing chronic inflammatory and metabolic disorders without the adverse effects often associated with traditional pharmaceutical treatments.